Helius Medical Technologies Launches Revelation Neuro
Helius Medical Technologies, Inc. (Nasdaq:HSDT), a leader in neurotechnology, has recently announced the establishment of its new wholly owned subsidiary, Revelation Neuro, Inc. This new venture is dedicated to developing non-implantable Brain-Computer Interface (BCI) technology, propelled by artificial intelligence (AI). The mission is clear: to enhance personalized neurorehabilitation methods, targeting individuals facing significant neurological challenges.
Revelation Neuro's Vision for Neurorehabilitation
Dane Andreeff, President and Chief Executive Officer of Helius, expressed excitement about the formation of Revelation Neuro. The focus will be on creating a new gold standard for care in neurorehabilitation that incorporates AI to optimize treatment pathways. "Our technology promises a less invasive method by utilizing non-implantable solutions, significantly reducing the risks associated with traditional procedures," he said. This commitment to safety and efficacy sets a solid foundation for future breakthroughs in the field.
Building on a Robust Foundation of Intellectual Property
The establishment of Revelation Neuro is backed by Helius's extensive intellectual property portfolio and a robust data warehouse. This strategic advantage will facilitate the development of AI algorithms tailored for BCI technology. With over five years of clinical evidence showcasing movement dysfunction in more than 400 subjects, the company aims to refine its algorithms, ensuring a tailored approach for each patient.
The use of translingual stimulation to modulate brain processes stands at the heart of Revelation Neuro's innovative approach. By leveraging this technology, the company intends to trigger therapeutic neuroplasticity without the complications linked to invasive implantation. Such an approach has the potential not only for motor function rehabilitation but also for addressing cognitive deficits and mood disorders in the future.
Funding the Future of Neuromodulation
Helius is working strategically to ensure that Revelation Neuro thrives and grows without direct additional investments from Helius itself. The company plans to channel the resources necessary for the subsidiary through third-party financing. With over $70 million already invested in the development of neuromodulation technology, Helius is poised to capitalize on this financial groundwork. This strategic positioning should allow Revelation Neuro to innovate and expand rapidly.
Participation at the Roth Conference
Helius Medical Technologies will also showcase its advancements at the upcoming 37th Annual Roth Conference. Scheduled for Monday, March 17, the presentation will include insights from key executives including Dane Andreeff and Jeff Mathiesen. Participants can anticipate a detailed overview of Helius’s strategic plans and their innovative approaches in the neurotech landscape. The event promises to be an enlightening opportunity for investors and stakeholders alike to engage with Helius’s growth trajectory.
About Helius Medical Technologies
Helius Medical Technologies is at the forefront of neurotechnology innovation, dedicated to improving the lives of those impacted by neurologic conditions. Their flagship product, the Portable Neuromodulation Stimulator (PoNS), reflects the company's commitment to enhancing the brain's ability to adapt and heal through non-invasive means. As the company prepares to expand its offerings through Revelation Neuro, it remains dedicated to pioneering solutions that empower patients on their road to recovery.
Frequently Asked Questions
What is Revelation Neuro?
Revelation Neuro is a wholly owned subsidiary of Helius Medical Technologies focused on developing non-implantable BCI technology powered by AI.
What technology does Helius Medical Technologies utilize?
Helius utilizes translingual stimulation to modulate brain processes to trigger therapeutic responses without the need for invasive procedures.
How does Revelation Neuro plan to finance its operations?
The subsidiary is expected to be financed through third-party sources rather than significant additional investments from Helius itself.
What will be the main focus of Revelation Neuro?
The primary goal of Revelation Neuro is to maximize the benefits of neuromodulation through AI optimization for personalized rehabilitation.
When will Helius present at the Roth Conference?
Helius is set to present at the Roth Conference on Monday, March 17 at 12:00 PM PT, sharing insights into their current and future operations.
